Spain ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis

Spain Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Executive Analysis

The Spain Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market size is at around $571 Mn in 2022 and is projected to reach $944 Mn in 2030, exhibiting a CAGR of 6.5% during the forecast period. The budget allotted to the Ministry of Health in 2023 will rise by 6.5%, totaling $3300.96 Mn, in the setting of a decentralized healthcare system where spending by the Spanish Ministry of Health accounts for less than 3% of total government spending. The allocation of money from both the national public budget for 2023 and the European Recovery and Resilience Facility are included in this sum. Notably, $3.40 Mn and $4.47 Mn are allotted to the newly established nationwide Public Health Agency and the nationwide network for public health surveillance, respectively. The coordinated purchase of the COVID-19 vaccine is also allocated $1400.30 Mn. The Ministry of Health has budgeted over $1276.87 Mn to upgrade primary care facilities and equipment for specialized care, screening programs, and psychiatric healthcare. These funds have been specifically designated for the improvement of primary care. This money will be distributed to the autonomous communities.

In childhood and teenage years, attention deficit hyperactivity disorder (ADHD) is one of the most prevalent mental health and behavioral disorders. The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) published by the American Psychiatric Association describes ADHD in children and adolescents under the age of 17 as the presence of six or more symptoms in either the inattentive or the hyperactive and impulsive domains, or both. According to previously conducted studies, the frequency of ADHD in Spain would be 3–14% in children between the ages of 8–15 in Valencia, 4-6% in children between the ages of 6–15 in Seville, and 1% in children between the ages of 6–8 in Navarre. Over the span of the years examined, the majority of studies looking at the long-term incidence of ADHD found an increasing trend in the incidence rate. In Spain, the use of ADHD medications has also been on the rise over time.

The majority of professional practice guidelines advocate for a multimodal strategy for treating psychological and academic issues, including pharmacological therapy and psychosocial interventions. Methylphenidate and atomoxetine, whose use has significantly increased in recent decades, are the only medications approved for the treatment of ADHD that are presently available in Spain. When a child between the ages of 3 and 12 is identified with ADHD, it is advised that behavioral and psychoeducational training programs for parents be provided first. The integration of adults with ADHD into the workforce can be facilitated and maintained with the help of cognitive behavioral programs. Psychoeducation regarding the biopsychosocial character of ADHD and skill development aimed at enhancing functioning and adaptability at work may be included in these programs.

Children under the age of six should not receive pharmacological medication for ADHD. When psychoeducational and/or psychological therapies have failed to treat ADHD symptoms in children and teenagers older than six years old, or when the patient is significantly impacted by their symptoms, pharmacological therapy is advised. According to these recommendations, methylphenidate, lisdexamfetamine, guanfacine, and atomoxetine are approved in Spain for the therapy of ADHD in kids and teenagers. In individuals with moderate to severe symptoms of ADHD, pharmacological therapy is advised as the first line of treatment. Adults with more subdued ADHD symptoms may benefit from either non-pharmacological or pharmacological therapies. Methylphenidate, lisdexamfetamine, atomoxetine, and guanfacine are medications for ADHD that have been approved in Spain. Its use in individuals with cardiac disease, whether diagnosed or undiagnosed, may be debatable due to adverse cardiovascular effects, primarily elevated blood pressure and heart rate.

Market Dynamics

Market Growth Drivers

In Spain, both the general public and medical professionals are becoming more conscious of ADHD, which has increased the number of cases where the disorder is identified. The Spain ADHD therapeutics market is expanding as a result of fresh and cutting-edge treatment choices, such as non-stimulant drugs and behavioral therapies. Also anticipated to fuel the rise of the Spain ADHD therapeutics market are the major companies concentrating on research and development for the treatment of ADHD.

Market Restraints

ADHD treatment and diagnosis services in Spain might be in short supply, especially in some areas and there is still a stigma associated with ADHD, and incorrect information about the condition may result in misdiagnosis and neglect. The proper criteria for diagnosing ADHD are still up for discussion, which could result in variations in diagnosis and treatment among different healthcare professionals thereby slowing the growth of Spain ADHD therapeutics market. Although medication can be useful in treating the symptoms of ADHD, some patients may be unable to use it due to possible side effects further limiting the growth of the market.

Competitive Landscape

Key Players

• Formune (ESP)
• Cinfa (ESP)
• Rioja Nature Pharma (ESP)
• Eggnovo (ESP)
• Casen Recordati (ESP)
• AbbVie
• ABITEC
• Actylis
• Adare Pharma
• Ajinomoto Bio-Pharma
• Alcami
• Aptar Pharma
• Artcraft Health

Healthcare Policies and Regulatory Landscape

The Spanish Agency for Medicine and Health Products (AEMPS) evaluates and approves medicines for human and animal use. AEMPS oversees the efficacy and safety of medications, certifies and inspects pharmaceutical laboratories, and combats the use of illicit drugs and substandard medical supplies. Despite its modest beginnings, the Spanish pharmaceutical industry anticipates a steady demand for pharmaceuticals. The AEMPS must give their seal of approval before any medication or biological product can be sold in Spain. Any novel pharmaceutical product must be registered through a Marketing Authorization Application (MAA) in accordance with Directive 2001/83/EC. The budgets of Spain's 17 autonomous regions contain public money that are used to pay for the reimbursement of pharmaceuticals. As a result, the regions take part in the Ministry of Health group that evaluates requests for medicine pricing and reimbursement.